CD160 and neoplasm: ACM derived from OGJ patients with early-stage and late-stage tumours increased the expression of CD160 on the surface of CD4+ T cells (untrx: 1.18 ± 0.2 vs. early-stage: 3.30 ± 0.5%, p = 0.01, late-stage: 4.82 ± 1.1%, p = 0.007) and CD8+ T cells (untrx: 0.73 ± 0.1 vs. early-stage: 2.51 ± 0.7%, p = 0.01, late-stage: 3.32 ± 1.2%, p = 0.04) compared with untreated cells (Fig. 2B).